NCT00363545View on ClinicalTrials.gov

To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,274

Participants

Timeline

Start Date

September 1, 2006

Primary Completion Date

April 12, 2007

Study Completion Date

April 12, 2007

Conditions
Infections, Rotavirus
Interventions
BIOLOGICAL

Lyophilized formulation of HRV vaccine

Lyophilized formulation of HRV vaccine

BIOLOGICAL

Liquid formulation of HRV vaccine

Liquid formulation of HRV vaccine

Trial Locations (3)

Unknown

GSK Investigational Site, David

GSK Investigational Site, La Chorrera

GSK Investigational Site, Panama City

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00363545 - To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) | Biotech Hunter | Biotech Hunter